BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2479410)

  • 1. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype.
    Shichishima T; Saitoh Y; Terasawa T; Noji H; Kai T; Maruyama Y
    Br J Haematol; 1999 Feb; 104(2):303-6. PubMed ID: 10050712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the Inab phenotype.
    Tate CG; Uchikawa M; Tanner MJ; Judson PA; Parsons SF; Mallinson G; Anstee DJ
    Biochem J; 1989 Jul; 261(2):489-93. PubMed ID: 2476116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Inab phenotype: characterization of the membrane protein and complement regulatory defect.
    Telen MJ; Green AM
    Blood; 1989 Jul; 74(1):437-41. PubMed ID: 2473800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
    Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
    Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
    Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
    Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency).
    Reid ME; Mallinson G; Sim RB; Poole J; Pausch V; Merry AH; Liew YW; Tanner MJ
    Blood; 1991 Dec; 78(12):3291-7. PubMed ID: 1720702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
    J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
    Ninomiya H; Kobayashi T; Abe T
    Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
    Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
    Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    Davitz MA; Low MG; Nussenzweig V
    J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria.
    Zalman LS; Wood LM; Frank MM; Müller-Eberhard HJ
    J Exp Med; 1987 Feb; 165(2):572-7. PubMed ID: 2434597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
    Kawakami Z; Ninomiya H; Tomiyama J; Abe T
    Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
    Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
    Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
    Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunocytochemical staining of decay-accelerating factor (DAF) on erythrocytes: paroxysmal nocturnal hemoglobinuria (PNH)].
    Kobayashi T; Nakazawa M; Sato Y; Tomiyama J; Ninomiya H; Abe T; Terasawa T; Shichishima T; Fujita T
    Rinsho Ketsueki; 1992 Feb; 33(2):162-6. PubMed ID: 1378912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor.
    Lederman MM; Purvis SF; Walter EI; Carey JT; Medof ME
    Proc Natl Acad Sci U S A; 1989 Jun; 86(11):4205-9. PubMed ID: 2471198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.